Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

33.44 -0.28 (-0.85%)

Streaming Delayed Price Updated: 11:56 AM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	228,079
Open	33.91
Bid (Size)	33.43 (200)
Ask (Size)	33.44 (200)
Prev. Close	33.72
Today's Range	33.31 - 33.96
52wk Range	17.23 - 33.89
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

December 12, 2025

From Genmab A/S

Via Business Wire

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

December 08, 2025

From Genmab A/S

Via Business Wire

Performance

YTD	+59.2%	+59.2%
1 Month	+6.5%	+6.5%
3 Month	+15.9%	+15.9%
6 Month	+61.3%	+61.3%
1 Year	+62.5%	+62.5%

More News

Analyst Expectations For Genmab's Future ↗

September 24, 2025

Via Benzinga

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

December 07, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

December 06, 2025

From Genmab A/S

Via Business Wire

Genmab (GMAB) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer ↗

November 18, 2025

Via Benzinga

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

November 18, 2025

From Genmab A/S

Via Business Wire

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗

November 12, 2025

Via Investor's Business Daily

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday ↗

November 10, 2025

Via Benzinga

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Genmab A/S

Via Business Wire

Why Is Genmab Stock Trading Lower On Monday? ↗

October 20, 2025

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

October 18, 2025

From Genmab

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

October 07, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Why Genmab Stock Popped on Friday ↗

October 03, 2025

Via The Motley Fool

Curious about the stocks that are showing activity after the closing bell on Friday? ↗

October 03, 2025

Via Chartmill

Why Genmab Stock Was Marching Higher Today ↗

September 30, 2025

Via The Motley Fool

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

September 29, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough ↗

September 29, 2025

Via Benzinga

Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus ↗

September 29, 2025

Via Investor's Business Daily

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

September 03, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria ↗

September 03, 2025

Via Chartmill

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?

Yes, Genmab A/S - American Depositary Shares is publicly traded.

What exchange does Genmab A/S - American Depositary Shares trade on?

Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Genmab A/S - American Depositary Shares?

The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market

What is the current price of Genmab A/S - American Depositary Shares?

The current price of Genmab A/S - American Depositary Shares is 33.44

When was Genmab A/S - American Depositary Shares last traded?

The last trade of Genmab A/S - American Depositary Shares was at 12/26/25 11:56 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433